---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-056925"
form_type: "8-K"
ticker: "DNTH"
cik: "0001690585"
company_name: "Dianthus Therapeutics, Inc. /DE/"
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:24:54.868739+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Dianthus Therapeutics Q1 net loss $13.7M; cash $377M funds into 2H 2027

## Summary
- Net loss $13.7M ($0.54/share) vs $7.1M ($8.10/share) in Q1 2023.
- Cash, equivalents, short-term investments $377M post $230M Jan 2024 PIPE.
- Phase 2 MaGic trial in gMG ongoing; top-line results expected 2H 2025.
- MMN Phase 2 trial to start Q2 2024; CIDP Phase 2 trial in 2H 2024.
- R&D expense $13.1M (incl. $0.8M SBC); G&A $5.6M (incl. $1.2M SBC).

## SEC filing metadata
- accession: 0000950170-24-056925
- form_type: 8-K
- ticker: DNTH
- cik: 0001690585
- company_name: Dianthus Therapeutics, Inc. /DE/
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1690585/000095017024056925/0000950170-24-056925-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1690585/000095017024056925/dnth-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-056925
- JSON: https://secwatch.observer/filing/0000950170-24-056925.json
- Plain text: https://secwatch.observer/filing/0000950170-24-056925.txt

## Key facts
- Earnings Releases
  Dianthus Therapeutics, Inc. /DE/ reported the quarter ended March 31, 2024 results: net income $13.7 million, EPS $0.54 net loss per share (basic and diluted).
  - Period: the quarter ended March 31, 2024
  - Net income: $13.7 million
  - EPS: $0.54 net loss per share (basic and diluted)
  - Result: reported results
  source text: Net loss for the quarter ended March 31, 2024 was $13.7 million or $0.54 net loss per share (basic and diluted)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1690585/000095017024056925/0000950170-24-056925-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.